Related Experiment Videos
Human immunodeficiency virus type 1 major neutralizing determinant exposed on hepatitis B surface antigen particles
K Schlienger1, M Mancini, Y Rivière
1Unité de Recombinaison et Expression Génétique, Institut National de la Santé et de la Recherche Médicale U163, Institut Pasteur, Paris, France.
Abstract:
Hepatitis B surface antigen (HBsAg) produced by recombinant DNA technology is now widely and safely used worldwide for hepatitis B vaccination. We used the HBsAg particle as a carrier molecule for presentation of selected human immunodeficiency virus type 1 (HIV-1) determinants to the immune system. Immunization of rhesus monkeys with an HBsAg chimera carrying the HIV-1 envelope major neutralizing determinant allowed us to generate proliferative T-cell responses and, in some cases, neutralizing antibodies and antibody-dependent cellular cytotoxicity. Since there is an overlap between populations at risk for hepatitis B virus and HIV, HBsAg recombinant particles may be relevant carriers for HIV-1 epitopes and could offer a new approach to the development of an AIDS vaccine.